Sumit Aggarwal - Jan 25, 2023 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Sumit Aggarwal
Stock symbol
ELOX
Transactions as of
Jan 25, 2023
Transactions value $
$0
Form type
4
Date filed
1/27/2023, 03:04 PM
Previous filing
Dec 3, 2021
Next filing
Jan 26, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELOX Stock Options (Right to Buy) Award $0 +68.7K $0.00 68.7K Jan 25, 2023 Common Stock 68.7K $4.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Remarks:

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.